For baby boomers, ultra-safe dividend stocks like these five that can add passive income streams to Social Security benefits.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

NEW YORK, NY / ACCESS Newswire / March 11, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Merck, known for its prescription medicines, vaccines, and biologic therapies, has been a dominant force in oncology treatment, primarily due to the success of Keytruda. However, recent developments ...

(RTTNews) - Merck (MRK), known as MSD outside the U.S., and Canada, Tuesday has inaugurated a new $1 billion, 225,000-square-foot vaccine manufacturing facility at its Durham, North Carolina ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...